Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients (Acclaim-3)

Condition:   Small Cell Lung Cancer Extensive Stage Interventions:   Biological: quaratusugene ozeplasmid;   Biological: atezolizumab Sponsor:   Genprex, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials